Respiratory Diseases Vaccines Markets, 2020-2025 by Infection, Type, Age Group, Geography and the Impact…

first_img Facebook Facebook By Digital AIM Web Support – February 19, 2021 Previous articleFrance scrumhalf Antoine Dupont tests positive for COVID-19Next articleIDEA public schools logo RGB.jpg Digital AIM Web Support Pinterest Respiratory Diseases Vaccines Markets, 2020-2025 by Infection, Type, Age Group, Geography and the Impact of Covid-19 – ResearchAndMarkets.com WhatsApp WhatsAppcenter_img TAGS  DUBLIN–(BUSINESS WIRE)–Feb 19, 2021– The “Global Respiratory Diseases Vaccines Market by Infection, Type, Age Group, Geography and the Impact of Covid-19 (2020-2025)” report has been added to ResearchAndMarkets.com’s offering. The market is driven by factors such as the increasing prevalence of respiratory diseases, a growing number of vaccines under trial, etc. While the lack of inadequate delivery infrastructure and limited consumer awareness are some of the restraining factors. Increasing R&D expenditure and the increasing availability of vaccines through various collaborations is creating opportunities for market growth. Respiratory Disease Vaccine Market: Introduction Respiratory disease affects the lungs and other parts of the respiratory system. In addition to tobacco smoke, other risk factors include air pollution, occupational chemicals and dust, and frequent lower respiratory infections during childhood. Chronic respiratory diseases (CRDs) are diseases of the airways and other structures of the lung. Some of the most common is chronic obstructive pulmonary disease (COPD), asthma, occupational lung diseases, and pulmonary hypertension. Treatments for each chronic respiratory disease vary and the ideal solution is the reduction and avoidance of risk factors. Neither asthma nor chronic obstructive pulmonary disease (COPD) can be cured but treatments can reduce symptoms, prevent escalation, and improve quality of life. Population protection by vaccination against infections has been one of the major achievements of public health and is of considerable importance in controlling respiratory diseases. The report offers a comprehensive evaluation of the global respiratory disease vaccine market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies. The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry. The report includes in-depth market analysis using Porter’s 5 force model. The impact of Covid-19 on the market is also featured in the report. Key Topics Covered: 1 Introduction 1.1 Objectives of the study 1.2 Market Definition 1.3 Currency 1.4 Years Considered for the study 1.5 Language 1.6 Key Benefits for Shareholders 2 Research Methodology 2.1 Research Process 2.2 Data Collection and Validation 2.3 Market Assessment 2.4 Assumptions of the Study 2.5 Limitations of the Study 3 Executive Summary 4 Market Overview 4.1 Introduction 4.2 Global Respiratory Disease Vaccine Market Size, by Geography 5 Market Dynamics 5.1 Drivers 5.2 Restraints 5.3 Opportunities 5.4 Trends 6 Market Analysis 6.1 Porter’s Five Forces Analysis 6.2 Impact of COVID-19 7 Global Respiratory Disease Vaccine Market, By Infection 7.1 Introduction 7.2 Influenza Virus 7.3 Pertussis 7.4 Streptococcus Pneumoniae 7.5 Tuberculosis 8 Global Respiratory Disease Vaccine Market, By Type 8.1 Bacterial Vaccine 8.2 Combination Vaccine 8.3 Viral Vaccine 9 Global Respiratory Disease Vaccine Market, By Age Group 9.1 Adolescent Vaccination 9.2 Adult Vaccination 9.3 Infant Vaccination 10 Americas Respiratory Disease Vaccine Market 10.1 Argentina 10.2 Brazil 10.3 Canada 10.4 Mexico 10.5 United States 11 Europe, Middle East & Africa Respiratory Disease Vaccine Market 11.1 France 11.2 Germany 11.3 Italy 11.4 Netherlands 11.5 Qatar 11.6 Russia 11.7 Saudi Arabia 11.8 South Africa 11.9 Spain 11.10 United Arab Emirates 11.11 United Kingdom 12 Asia-Pacific Respiratory Disease Vaccine Market 12.1 Australia 12.2 China 12.3 India 12.4 Indonesia 12.5 Japan 12.6 Malaysia 12.7 Philippines 12.8 South Korea 12.9 Thailand 13 Competitive Scenario 13.1 Merger & Acquisition 13.2 Agreement, Collaboration, & Partnership 13.3 New Product Launch & Enhancement 13.4 Investment & Funding 13.5 Award, Recognition, & Expansion 14 Company Profiles 14.1 AstraZeneca 14.2 Bavarian Nordic 14.3 Bayer AG 14.4 Bio Farma 14.5 Dynavax Technologies Corporation 14.6 Emergent BioSolutions, Inc. 14.7 GlaxoSmithKline plc 14.8 Merck & Co., Inc. 14.9 Pfizer Inc. 14.10 Sanofi S.A. 14.11 Seqirus USA Inc. For more information about this report visit https://www.researchandmarkets.com/r/dddddb View source version on businesswire.com:https://www.businesswire.com/news/home/20210219005431/en/ CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: GENERAL HEALTH PHARMACEUTICAL HEALTH SOURCE: Research and Markets Copyright Business Wire 2021. PUB: 02/19/2021 12:11 PM/DISC: 02/19/2021 12:10 PM http://www.businesswire.com/news/home/20210219005431/en Twitter Pinterest Twitter Local NewsBusinesslast_img